NCT07319975

Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity

Comparison of the Effects of Semaglutide and Tirzepatide Treatments in Combination With Exercise in Obesity Management

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Istanbul Galata University · Academic / Other
• Sex: All
• Age: 25 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

Obesity is a growing global health problem that affects people of all ages. It can lead to serious health issues such as cardiovascular disease, insulin resistance, inflammation, and reduced physical function. New medications, including GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP agonists like tirzepatide, have been shown to help people lose significant weight. However, some of this rapid weight loss may come from a reduction in muscle mass rather than fat. Losing muscle can lower physical performance, impair metabolic health, and increase the risk of developing sarcopenic obesity. This study aims to compare the effects of pharmacological treatment alone with a combined treatment program that includes both medication and exercise in individuals with obesity. The primary objective is to evaluate how these two approaches influence body composition. The secondary objective is to examine the effects of pharmacological treatment versus combined treatment on cardiometabolic markers, peripheral muscle strength, functional capacity, respiratory function, respiratory muscle performance, and physical activity levels. The study seeks to determine whether adding structured exercise to medication can provide additional health benefits beyond weight loss.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	Semaglutide	They will use only semaglutide.
DRUG	Tirzepatide	They will use only tirzepatide.
BEHAVIORAL	Tirzepatide+Exercise	This group will engage in exercise and receive tirzepatide therapy."
BEHAVIORAL	Semaglutide+Exercise	This group will engage in exercise and receive semaglutide therapy."

Timeline

• Start date: 2025-12-29
• Primary completion: 2026-10-01
• Completion: 2026-12-01
• First posted: 2026-01-06
• Last updated: 2026-01-06

Locations

1 site across 1 country: Turkey (Türkiye)